December 25, 2010
/24-7PressRelease/ -- As more scientific data becomes available linking the drug Reglan (Metoclopramide) with a serious neurological disorder called tardive dyskinesia (TD), new products liability cases are being filed by former users of the drug around the country. Reglan is distributed in both brand and generic forms by a number of the nation's biggest drug manufacturers, including:
- Wyeth
- ANI Pharmaceuticals
- Baxter
- Teva
- Hospira/Mayne
- Actavis
Reglan was first put on the market in the 1980s as a treatment for severe Gastroesophageal Reflux Disease (GERD), a condition in which stomach acid and/or swallowed food rises from the patient's stomach back into the esophagus, causing a burning sensation, nausea, vomiting and tissue damage. Its ability to increase the rate of stomach and intestinal contractions also makes it effective at treating the nausea coming from anesthesia, certain chemotherapy drugs and morning sickness.
Because of its wide-ranging functionality, Reglan has been prescribed to millions of patients over the years, and it is still on the market today, albeit with strong warning labels and extreme caution. The link between Reglan and tardive dyskinesia was first discovered in 2009, and that prompted the U.S. Food and Drug Administration (FDA) to issue its "black box" warning advising prospective patients and physicians alike of the potential danger.
If you or a loved one has developed tardive dyskinesia after taking brand-name or generic Metoclopramide, consult an experienced personal injury and dangerous drugs attorney in your area to learn more about your legal rights and options.
Article provided by Riddle & Brantley LLP
Visit us at
www.justicecounts.com---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Findlaw PR:
